Repositioning Candidate Details
| Candidate ID: | R0495 |
| Source ID: | DB01330 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Cefotetan |
| Synonyms: | (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid; Cefotetan |
| Molecular Formula: | C17H17N7O8S4 |
| SMILES: | [H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O |
| Structure: |
|
| DrugBank Description: | A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. |
| CAS Number: | 69712-56-7 |
| Molecular Weight: | 575.619 |
| DrugBank Indication: | For prophylaxis and treatment of bacterial infections. |
| DrugBank Pharmacology: | Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. |
| DrugBank MoA: | The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis. |
| Targets: | Penicillin-binding protein 3 inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|